Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas
Top Cited Papers
- 1 March 2002
- journal article
- research article
- Published by Elsevier in European Journal Of Cancer
- Vol. 38 (4) , 543-549
- https://doi.org/10.1016/s0959-8049(01)00398-7
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Clinical Trial Designs for Cytostatic Agents: Are New Approaches Needed?Journal of Clinical Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Effect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 2000
- Phase II study of fotemustine in advanced soft tissue sarcomas: A trial of the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 1993
- Phase II study of miltefosine (Hexadecylphosphocholine) in advanced soft tissue sarcomas of the adult— An EORTC Soft Tissue and Bone Sarcoma Group studyEuropean Journal Of Cancer, 1993
- Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma GroupEuropean Journal Of Cancer, 1992
- Phase II study of nimustine in metastatic soft tissue sarcomaEuropean Journal of Cancer and Clinical Oncology, 1991
- High-dose DTIC in advanced soft-tissue sarcomas in the adultAnnals of Oncology, 1991
- Optimal two-stage designs for phase II clinical trialsControlled Clinical Trials, 1989
- The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agentJournal of Chronic Diseases, 1961